Allied-Bristol Life Sciences Forms Strategic Partnership with Synergy Partners R&D Solutions to Advance Biopharmaceutical Inn...
November 18 2014 - 2:00AM
Business Wire
- Synergy Partners offers significant
experience in drug discovery and development. Areas of specialty
include R&D strategy, medicinal chemistry, pharmacology,
metabolism, drug safety and clinical development.
- Synergy Partners will provide
strategic advice and scientific support to Allied-Bristol Life
Sciences’ R&D efforts.
Allied-Bristol Life Sciences, LLC, a biopharmaceutical
enterprise jointly owned between Allied Minds (LSE: ALM) and
Bristol-Myers Squibb Company (NYSE: BMY), today announced that it
formed a strategic partnership with Synergy Partners R&D
Solutions, LLC.
Synergy Partners, co-founded by Catherine D. Strader, Ph.D. and
James S. MacDonald, Ph.D., comprises a network of over 20
well-respected experts that collectively have taken more than 100
drugs from discovery through development. Their team of scientists
offers expertise in areas such as disease biology, medicinal
chemistry, process chemistry, toxicology, pharmacology and drug
safety, and have proven track records at many of the world’s
leading biopharmaceutical companies, including Bristol-Myers
Squibb, Merck & Co., AstraZeneca, Pfizer Inc., Johnson &
Johnson and Eli Lilly & Co.
This collective expertise offers essential insights for
Allied-Bristol Life Sciences’ efforts to identify the most
promising early-stage therapeutic opportunities at leading U.S.
academic research institutions, and transform them into robust
pre-clinical candidates for follow-on clinical development.
“The drug development team at Synergy Partners includes leaders
within the biopharmaceutical industry in diseases of high interest
to Allied-Bristol Life Sciences. We are pleased to have them
joining our team as we move forward with this unique opportunity to
advance academic innovations to drug candidates,” said Chris Silva,
Chief Executive Officer of Allied Minds.
Allied-Bristol Life Sciences was formed earlier this year to
identify discoveries from academic labs with promising therapeutic
and commercial potential, and to drive these early-stage
innovations from initial feasibility to pre-clinical candidacy.
Synergy Partners will assist these efforts by lending strategic
insights and decades of experience in the development, execution
and management of critical experiments and achievement of key
milestones needed to successfully advance each research
program.
“We are excited by the opportunity to work with
Allied-Bristol Life Sciences to build a portfolio
of novel and differentiated pre-clinical candidates,”
said Synergy Partners’ Strader. “Synergy Partners is committed to
bringing innovative new medicines to patients and Allied-Bristol
Life Sciences offers a terrific model for optimizing
innovation in the world of biopharmaceuticals.”
About Allied-Bristol Life Sciences
Allied-Bristol Life Sciences (ABLS) is a joint venture between
Allied Minds and Bristol-Myers Squibb Co. that aims to deliver the
important medicines for tomorrow. Based upon compelling biological
discoveries and insights from scientists at leading U.S. research
institutions, ABLS will identify, source and de-risk promising,
early-stage therapeutic opportunities, from discovery through
development, in key therapeutic areas, including fibrosis,
cardiovascular diseases, oncology, immunology, virology and
genetically defined diseases. For more information, visit
http://alliedminds.com/subsidiaries/allied-bristol.
About Allied Minds
Allied Minds (LSE: ALM) is an innovative U.S. science and
technology development and commercialization
company. Operating since 2006, Allied Minds forms, funds,
manages and builds products and businesses based on innovative
technologies developed at leading U.S. universities and federal
research institutions. Allied Minds serves as a diversified holding
company that supports its businesses and product
development with capital, central management and
shared services. More information about the Boston-based company
can be found at www.alliedminds.com.
Allied Minds Forward-Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company’s future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risk and uncertainties described in the risk factors
included in the company’s regulatory filings. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law, regulatory requirement, the Prospectus Rules, the
Listing Rules and the Disclosure and Transparency Rules, neither
the company nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
ArcPoint Strategic CommunicationsChristine Dunn, 617-484-1660
x101cdunn@arcpointstrategy.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024